- ►cardiobarbanza.com [PDF] DM Nathan, JB Buse, MB Davidson, E … - Diabetologia, 2009 - Springer Page 1. CONSENSUS STATEMENT UPDATE Medical management of hyperglycaemia in type
2 diabetes mellitus: a consensus algorithm for the initiation ... Cited by 1042 - Related articles - BL Direct - All 92 versions
DM Nathan, JB Buse, MB Davidson, RJ Heine … - Diabetes Care, 2006 - Am Diabetes Assoc The epidemic of type 2 diabetes in the latter part of the 20th and in the early
21st century, and the recognition that achieving specific glycemic goals can
substantially reduce morbidity, have made the effective treatment of ... Cited by 16 - BL Direct
JF Blickle - Diabetes and Metabolism, 2006 - Elsevier Glinides represent a chemically heterogeneous new class of insulinsecreting
agents characterized by a rapid onset and short duration of action. They act by
closure of the ATP-dependant K channel. Repaglinide, the only glinide ... Cited by 16 - Related articles - BL Direct - All 3 versions
A Golay - International Journal of Obesity, 2007 - nature.com Most patients with type 2 diabetes are overweight or obese, overweight or
obesity increases the risk of developing type 2 diabetes and obesity per se is
strongly associated with multiple cardiometabolic risk factors. However, ... Cited by 12 - Related articles - BL Direct - All 4 versions
M Monami, C Lamanna, N Marchionni, E … - Diabetes research and clinical practice, 2008 - Elsevier Metformin is recommended as first-line treatment in type 2 diabetic patients.
Several agents can be used as add-on treatments in metformin monotherapy
failure. Most available clinical trials on the hypoglycemic efficacy of ... Cited by 12 - Related articles - All 26 versions
J Li, H Tian, Q Li, N Wang, T Wu, Y Liu, Z Ni, … - Diabetes Obes Metab, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 8 - Related articles - All 5 versions
S Ristic, C Collober-Maugeais, E Pecher, F … - Diabetic Medicine, 2006 - pubmedcentral.nih.gov Re-use of this article is permitted in accordance with the Creative Commons
Deed, Attribution 2.5, which does not permit commercial exploitation. ... This
article has been cited by other articles in PMC. Cited by 8 - Related articles - BL Direct - All 7 versions
J Chalmers, JE Hunter, SJ Robertson, J Baird … - Current Medical Research and Opinion®, 2007 - informahealthcare.com J. Chalmersa, JE Huntera, sJ robertsona, J. Bairda, M. Martina, Ci Franksa, Cr
Whately-smithb, s. Marizc and iW Campbella ... Address for correspondence: Dr
J. Chalmers, Diabetes Centre, Victoria Hospital, Hayfield Road, Kirkcaldy, ... Cited by 8 - Related articles - BL Direct - All 5 versions
- ►qub.ac.uk [PDF] NA Duffy, BD Green, N Irwin, VA Gault, AM … - European journal of pharmacology, 2007 - Elsevier Dipeptidyl peptidase IV (DPP IV) is the primary inactivator of glucoregulatory
incretin hormones. This has lead to development of DPP IV inhibitors as a new
class of agents for the treatment of type 2 diabetes. Recent reports ... Cited by 6 - Related articles - All 6 versions
HS Chou, JP Palmer, AR Jones, B Waterhouse, … - Diabetes, obesity & metabolism, 2007 - interscience.wiley.com Methods: Drug-naive subjects (n = 901) were enrolled into this 28-week,
double-blind, parallel-group study if their glycosylated haemoglobin A 1c (HbA
1c ) was >7.5% but ≤12%. Subjects were randomized to receive either GLIM ... Cited by 6 - Related articles - All 4 versions
